

*CURRICULUM VITAE*

NAME: Richard Wesley Presnell, M.D.

OFFICE ADDRESS: 820 St. Sebastian Way, Suite 4A  
Augusta, GA 30901-2636

OFFICE TELEPHONE/FAX: (800) 445-3235 x 6374 / (303) 284-8829

PERSONAL:

DATE OF BIRTH: July 3, 1956

PLACE OF BIRTH: Pensacola, Florida, U.S.A.

CITIZENSHIP: American

SEX: Male

RACE: Caucasian

EDUCATION:

HIGH SCHOOL: Theodore High School, Theodore, AL 1971-1974

COLLEGE: University of South Alabama, Mobile, AL 1974-1978  
Major: Biology; Minor: Chemistry

MEDICAL SCHOOL: University of South Alabama, Mobile, AL 1978-1982

POST-DOCTORAL TRAINING: *Internship:* Internal Medicine: July 1, 1982-June 30, 1983  
Medical College of Georgia  
1120 15<sup>th</sup> Street  
Augusta, GA 30912  
(706) 721-0211

*Residency:* Neurology: July 1, 1983-June 30, 1984  
Medical College of Georgia  
1120 15<sup>th</sup> Street  
Augusta, GA 30912  
(706) 721-0211

*Residency:* Internal Medicine: January 1, 1985-June 30, 1986  
Medical College of Georgia  
1120 15<sup>th</sup> Street  
Augusta, GA 30912  
(706) 721-0211

BOARD CERTIFICATION: National Board of Medical Examiners: July 1, 1983  
Certificate # 261320

American Board of Internal Medicine: September 10, 1986  
Certificate # 107213

PROFESSIONAL:

July 1, 1984–  
December 31, 1984      Director, Emergency Department  
Jefferson County Hospital  
Louisville, GA  
(912) 625-7000

July 1, 1986–  
September 30, 1987:      Director, Internal Medicine Clinic  
Dwight D. Eisenhower Army Medical Center  
Fort Gordon, GA  
(706) 791-0110

October 1, 1987–  
June 30, 1995:      Medical Director, Internal Medicine and AIDS Clinics  
University Hospital  
1350 Walton Way  
Augusta, GA 30901  
(706) 722-9011

July 1, 1995–May 31, 2006: Private practice in Internal Medicine and HIV Management  
820 St. Sebastian Way, Suite 4A  
Augusta, GA 30901–2636  
(706) 724-4376

June 1, 2006–Present:      Associate Director, Medical Affairs, National Accounts  
Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, CA 94404  
(650) 522-6374

PROFESSIONAL:

ACADEMIC APPOINTMENTS: Assistant Clinical Professor of Medicine  
Medical College of Georgia

COMMITTEES:      Pharmaceutical and Therapeutics, University Hospital  
Ryan White Consortium, Central Savannah River Area  
Augusta Area Council on AIDS

ORGANIZATIONS:      American Medical Association  
American College of Physicians  
Southern Medical Association  
International AIDS Society  
International AIDS Society – USA  
American Academy of HIV Medicine  
American Society of Addiction Medicine

INVESTIGATOR IN PHARMACEUTICAL TRIALS:

Performance of Lopinavir/Ritonavir as an Alternative Treatment Option (PLATO): A Randomized, Phase IV Study to Evaluate the Quality of Life of Subjects Infected with HIV-1 and who are Intolerant to Their Current Antiretroviral Therapy and Alter Therapy to ABT-378/ritonavir. Protocol M00-267.

Abacavir (1592U89) Open Label Protocol for Adult Patients with HIV-1 Infection, Part B. Protocol CNAA3008.

A Phase IV, Open-Label Study to Assess the Safety and Tolerability of Ziagen<sup>®</sup> (abacavir) in HIV-1 Infected Individual and to Investigate the Effect of Baseline Genotype with Virtual Phenotype on the Response to Abacavir (Ziagen<sup>®</sup>) in Therapy Experienced Subjects in the Clinical Setting. ESS40009.

Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options. GS-00-955.

Protocol PR95-29-015 The Effect of Procrit<sup>®</sup> on the Quality of Life of HIV-Infected Patients; Phase IV Study.

NUCA 3004, 3TC Open Label Program.

A Non-Comparative, Multi-Site, Open-Label, 48 Week Study to Monitor the Safety and Tolerability of MK-0639 (Indinavir Sulfate) 800 mg q8h Administered As Monotherapy or in Combination with Reverse Transcriptase Inhibitor Therapy for the Treatment of HIV-1 Infection in Advanced AIDS Patients (Patients with CD4 Counts of 50 cell/mm<sup>3</sup> or less).

An open-label, non-randomized trial to evaluate the tolerability and safety of VIRAMUNE<sup>®</sup> (nevirapine) in adult and pediatric patients with progressive, symptomatic HIV disease.

Compassionate Use of Thalidomide in Adults with HIV-Associated Wasting, Protocol W-002.

A Multi-center, Open Label Study of Didanosine, Stavudine, and Nelfinavir.